Treatment of AD with Tralokinumab

Atopic dermatitis (AD) is a chronic, inflammatory skin disease associated with a plethora of both physical and psychological implications, including severe pruritus, widespread eczematous lesions, pain, sleep disruption, anxiety, and depression. Although it is a relatively common disease affecting pediatric and adult patients alike, few options exist to treat moderate-to-severe AD. Janus kinase (JAK) inhibitors, including abrocitinib and upadacitinib, have emerged as an option for the treatment of moderate-to-severe AD. However, clinical trials of JAK inhibitors have shown an increased risk of some infections such as herpes zoster. In recent years, tralokinumab—a human monoclonal antibody that binds directly to IL-13—has been proven to be a safe and efficacious treatment in several randomized, placebo-controlled trials, including ECZTRA 1, ECZTRA 2, and ECZTRA 3. In these clinical trials, patients receiving tralokinumab achieved both primary and secondary endpoints across both physical and psychological domains at significantly higher rates than patients who did not receive tralokinumab. Furthermore, no significant difference was found in the rates of herpes zoster between tralokinumab and placebo groups. Thus, tralokinumab represents a safe and efficacious treatment for moderate-to-severe atopic dermatitis.